ASH 2021 – Focused on CAR-T

The 2021 American Society of Hematology Annual Meeting (ASH) is taking place December 11-14, virtually and in-person in Atlanta, Georgia. This year’s program provides attendees with insights into the latest advances in hematology, including research highlighting the transformative role immunotherapies are playing in the treatment of major blood cancers. This page series will provide coverage of the highlights in chimeric antigen receptor (CAR) T-cell therapy being presented at the meeting, including:

  • New CAR T-cell therapy candidates across hematologic malignancies
  • Insights into the hematologic effects of COVID-19 infection
  • Analyses of real-world data of investigational and approved CAR T-cell therapies

Look out for coverage of the meeting and click here to learn more about the 2021 ASH Annual Meeting.

Anti-BCMA CAR T-Cell Therapy CT103A Provides Rapid, Durable Responses

In a single-arm phase I/II study, infusion with CT103A, a novel fully human B-cell maturation antigen (BCMA)-targeted chimeric antigen...

Tisa-Cel Found Noninferior to Standard of Care in Relapsed/Refractory Aggressive B-Cell NHL

According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who received...

ZUMA-7: Benefits of Axi-Cel Persist Over Current Standard of Care in Aggressive B-Cell Lymphoma

The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated significant and clinically meaningful improvement in event-free survival...

Axicabtagene Ciloleucel Produces High Complete Response Rates in Large B-Cell Lymphoma

First-line treatment with the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) led to rapid responses...

Anti-BCMA CAR T-Cell Therapy CT103A Provides Rapid, Durable Responses

In a single-arm phase I/II study, infusion with CT103A, a novel fully human B-cell maturation antigen (BCMA)-targeted chimeric antigen...
CANTATA – Addition of a Glutaminase Inhibitor to Cabozantinib Fails to Improve Survival in Renal Cell Carcinoma

CAR T-Cell Therapy Recipients May Have Higher Unplanned Use of Healthcare Resources

Chimeric antigen receptor (CAR) T-cell therapy is a potentially life-saving option for patients with hematologic cancers, but it may...

Curated Journal Abstracts

Advertisement
Advertisement